國家衛生研究院 NHRI:Item 3990099045/12268
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 917221      在线人数 : 1488
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/12268


    题名: Evaluation of efficacy of nivolumab by baseline factors from ATTRACTION-2
    作者: Kang, YK;Satoh, T;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yoshikawa, T;Oh, SC;Tamura, T;Lee, KW;Morita, S;Chen, LT;Boku, N
    贡献者: National Institute of Cancer Research
    摘要: Background: Nivolumab (Nivo) has shown superior efficacy with manageable safety for G/GEJ cancer refractory to, or intolerant of, standard chemotherapy in phase 3 study (ATTRACTION-2). Subgroup analysis of OS according to baseline demographics and disease characteristics favored Nivo over placebo in all subgroups. However, about half of patients had early disease progression even after administration of Nivo. Here, we explored factors of patients who had early progression after administration of Nivo. Methods: A statistical random forest method, a type of machine learning method, was used to explore clinical factors that could contribute to early progression after Nivo. In this analysis, the outcome variable was 56-day PD rate and covariates were patients’ clinical background factors. Factors were explored by comparing Nivo and placebo arms in all subgroups, constructed with 1) every single factor; 2) every pair of factors coming from the covariates. Results: In a single factor extraction, hyponatremia was identified as the most highly contributing factor to early progression. Of 330 patients in the Nivo arm, 59 patients showed hyponatremia at the baseline. Importantly, in a pair factor extraction, the patient population with hyponatremia and any of high NLR (N = 31, 9.4%, cut off; second tertile), high neutrophil (N = 28, 8.5%, cut off; second tertile), PS1 (N = 50, 15.2%) or no prior use of ramucirumab (N = 55, 16.7%), were found as risk factors of early progression in Nivo. PFS-KM curves were almost overlapped between Nivo and placebo arms in these patients with any pair of these risk factors. Conclusions: Our exploratory analysis suggested that a patient population with both ‘poor general condition’ represented by hyponatremia and PS 1, and ‘inflammatory conditions’ represented by high NLR and/or high neutrophil count, would be potential risk factors associated with early progression. This needs further validation with other potential biomarkers in tumor tissue and additional studies. Additional analysis with biomarkers such as PD-L1 will be presented at the meeting. Clinical trial information: NCT02267343.
    日期: 2019-02
    關聯: Journal of Clinical Oncology. 2019 Feb;37(4, Suppl.):Abstract number 8.
    Link to: http://dx.doi.org/10.1200/JCO.2019.37.4_suppl.8
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0732-183X&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000489107600056
    显示于类别:[陳立宗] 會議論文/會議摘要

    文件中的档案:

    没有与此文件相关的档案.



    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈